Article info

Download PDFPDF

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Authors

  1. a adusumip{at}mskcc.org
  2. b cha.edward{at}gene.com
  3. c mcornfeld{at}iderapharma.com
  4. d tdavis{at}celldextherapeutics.com
  5. e ADiab{at}mdanderson.org
  6. f tdubensky{at}aduro.com
  7. g eevans{at}vaccinex.com
  8. h jgrogan{at}gene.com
  9. i birving{at}cytomx.com
  10. j rom.leidner{at}providence.org
  11. k olwill{at}pieris.com
  12. l pss{at}nantworks.com
  13. m ftriebel{at}immutep.com
  14. n dptuck{at}gmail.com
  15. o abot{at}kitepharma.com
  16. p roger.dansey{at}merck.com
  17. q cgd2139{at}cumc.columbia.edu
  18. r gordon_freeman{at}dfci.harvard.edu
  19. s ribrahim{at}parkerici.org
  20. t salil.patel{at}bms.com
  21. u chen.daniel{at}gene.com
View Full Text

Citation

Adusumilli PS, Cha E, Cornfeld M, et al
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Publication history

  • Received March 27, 2017
  • Accepted May 31, 2017
  • First published June 20, 2017.
Online issue publication 
June 20, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.